

SEP 02 2008

LAW OFFICES  
THE NEEDLE & ROSENBERG INTELLECTUAL PROPERTY PRACTICE OF  
**BALLARD SPAHR ANDREWS & INGERSOLL, LLP**  
999 PEACHTREE STREET, SUITE 1000  
ATLANTA, GEORGIA 30309-3915  
678-420-9300  
FAX: 678-420-9301  
WWW.BALLARDSPAHR.COM

BALTIMORE, MD  
BETHESDA, MD  
DENVER, CO  
LAS VEGAS, NV  
LOS ANGELES, CA  
PHILADELPHIA, PA  
PHOENIX, AZ  
SALT LAKE CITY, UT  
VOORHEES, NJ  
WASHINGTON, DC  
WILMINGTON, DE

**IMPORTANT FAX DOCUMENT**

---

**DATE** September 2, 2008

**NAME** Examiner Laura Goddard  
U.S. Patent and Trademark

**YOUR REF NO.** U.S. Application No. 10/693,030  
273-8300

**FAX NUMBER** 571-272-8788

---

**FROM** Janell T. Cleveland, Patent Agent (Reg. No. 53,848)

**OUR REFERENCE NO.** 14014.0306U2

**OUR FAX NUMBER** 678-420-9301

**NUMBER OF PAGES** 2 (Including Cover Page)

---

**Re:** U.S. Application No. 10/693,030, filed 10/24/2003  
(Divisional of U.S. Application No. 09/170,699, filed October 13, 1998)  
Title: "METHODS FOR DIAGNOSIS OF CANCER USING erbB-3"  
Inventors: Kraus et al.

Dear Examiner Goddard, Thank you for taking the time to speak with me tomorrow. I have attached a proposed amendment to claim 43. What we were trying to do by adding new claims 60-79 was to overcome the priority rejection for the pending claims. However, claims 60-79 came under a restriction requirement. Normally this wouldn't be a problem and we would file a divisional, however, we are facing the expiration of the patent in 2009 and the divisional probably wouldn't even be examined by then. So what I've done is try to amend claim 43 so it no longer has a priority problem. Of course I understand that we need to do a response to have the claim examined, but I was hoping to at least explain what we were trying to do by amending it. By the way, specific basis for amended claim 43 can be found in the earliest priority document (US Patent 5,183,884) in the specification in Example 5, in the last paragraph before Example 1, and in the eighth paragraph of the "summary". (I apologize for the unconventional format of listing where basis can be found, but I only have the online version of the patent and don't have page numbers). Thanks, and I look forward to speaking with you tomorrow. /Janell Cleveland/

**CONFIDENTIALITY NOTE**

*The information contained in this facsimile message is privileged and confidential and is intended only for the use of the individual or entity named above and others who have been specifically authorized to receive it. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communications is strictly prohibited. If you have received the communications in error, or if any problems occur with transmission, please notify us immediately by telephone. Thank you*

ATTORNEY DOCKET NO. 14014.0306U2  
App. No. 10/693,030

43. (Previously Presented) A method of ~~classifying a cancer as being correlated with a greater amount of~~ determining expression of an erbB-3 gene ~~as compared to a control,~~ comprising:

a) ~~measuring~~ surveying the level of expression of the erbB-3 gene in a sample from a subject diagnosed with cancer; and

b) ~~comparing~~ determining the level of expression of the erbB-3 gene in the sample from the subject to the level of expression of the erbB-3 gene in a sample from a control subject, whereby a greater amount of expression of the erbB-3 gene in the sample from the subject, relative to the level of expression of the erbB-3 gene in the sample from the control subject, wherein overexpression of erbB-3 is classifies the cancer as being correlated with a greater amount of expression of the erbB-3 gene human malignancy.